Search

Displaying results 3001 - 3010 of 10000 in total
  1. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  2. Drug

    Umbilical Cord Blood Hematopoietic Stem Cells

    go.drugbank.com/drugs/DB15723
    Investigational

    HUCBC CD34+ cells are cultured with various cytokines and interleukins to give rise to various cell types, from red blood cells, to B-, T-, and Natural Killer Cells. … Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels

  3. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.

  4. Drug

    Lactobacillus coryniformis K8

    go.drugbank.com/drugs/DB15733
    Experimental

    Lactobacillus is a common bacteria found in the gut with Lactobacillus coryniformis K8 being originally isolated from artisan goat cheese.

  5. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). … TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.

  6. Drug

    Washed Microbiota Transplantation

    go.drugbank.com/drugs/DB15745
    Investigational

    Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn … The resulting suspension is shown to decrease FMT-related adverse events.

  7. Drug

    Interferon Kappa

    go.drugbank.com/drugs/DB15749
    Experimental

    Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and … a 27-amino acid signal peptide conserved in type I interferons.

    Synonyms: IFN‐κ
  8. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins.

  9. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    The interferon is primarily produced by activated T lymphocytes and natural killer cells. … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions.

    Synonyms: IFN-G, IFN-γ
  10. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on … Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors

    Categories: Interleukin-6 Receptor AntagonistSynonyms: Humanised anti-IL-6 receptor monoclonal antibody